---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-121607"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2022-04-27T23:59:59+00:00"
generated_at: "2026-06-26T04:09:36.589154+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences restructures, cuts 35% of staff; Q1 net loss $25.3M; COO resigns

## Summary
- Headcount reduced ~35% to align resources behind SGT-001 and SGT-003; cash runway extended into Q2 2024.
- COO Joel Schneider to resign effective May 27, 2022 to become CEO of a private gene therapy company.
- Q1 net loss $25.3M vs $16.9M YoY; collaboration revenue $1.9M (down from $3.3M); R&D expense $19.9M.
- Cash, equivalents and securities $180.1M as of March 31, 2022.
- SGT-003 IND submission expected early 2023; SGT-001 transitioning to commercial-scale manufacturing.

## SEC filing metadata
- accession: 0001193125-22-121607
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2022-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312522121607/0001193125-22-121607-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312522121607/d326843d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-121607
- JSON: https://secwatch.observer/filing/0001193125-22-121607.json
- Plain text: https://secwatch.observer/filing/0001193125-22-121607.txt

## Key facts
- Executive change
  Joel Schneider resigned as Chief Operating Officer at Solid Biosciences Inc..
  - Action: resigned
  - Role: Chief Operating Officer
  source text: Joel Schneider, Chief Operating Officer of the Company, notified the Company of his intent to resign to accept a role as chief executive officer of a privately-held novel, viral-based gene therapy platform company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312522121607/0001193125-22-121607-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.